
As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma
Two months after Enrique Conterno left his high-profile post as the head of Lilly Diabetes and Lilly USA, the 27-year pharma vet is back in the game — this time as the newly appointed CEO of a closely-watched biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.